Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453915 · ClinicalTrials.gov registry record · Early Phase 1
NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
A Early Phase 1 study of Positron Emission Tomography, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06453915 is a Early Phase 1 study of Positron Emission Tomography that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06453915, a Early Phase 1 study of Positron Emission Tomography, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD. The goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatment
Conditions Studied
Interventions
- DRUG 18F-DPA-714
- DRUG 18F-FDG
Study Locations (1)
California
- UC Davis EXPLORER Molecular Imaging Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2027-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06453915
The ClinicalTrials.gov registry entry for NCT06453915 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Positron Emission Tomography appearing as the primary indexed condition, and to 2 interventions - of which 18F-DPA-714 is the first listed.
NCT06453915 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06453915 about?
NCT06453915 is a clinical study titled "NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease". Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one...
What is the current status of trial NCT06453915?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2025-04-30. Estimated completion is 2027-07.
What conditions does trial NCT06453915 study?
This clinical trial studies the following conditions: Positron Emission Tomography.
What interventions are being tested in trial NCT06453915?
The interventions under investigation include: 18F-DPA-714 (DRUG), 18F-FDG (DRUG).
Who is sponsoring clinical trial NCT06453915?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06453915 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Positron Emission Tomography
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.